Document:

EX-4.3

 Exhibit 4.3 

EXAGEN DIAGNOSTICS, INC. 

FOURTH AMENDED AND RESTATED 

STOCKHOLDERS’ AGREEMENT 

THIS FOURTH AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (this “Agreement”) is made as of October 4, 2013, by and
among Exagen Diagnostics, Inc., a Delaware corporation (the “Corporation”), and the persons listed on Schedule A hereto (the “Investors”). 

RECITALS 
 WHEREAS, the
Investors are party to that certain Third Amended and Restated Stockholders Agreement of the Corporation dated September 4, 2012 (as amended, the “Prior Agreement”); and 

WHEREAS, certain of the Investors and the Corporation have entered into that certain Series D Preferred Stock Purchase Agreement dated the
date hereof (the “Series D Purchase Agreement”), pursuant to which such Investors agreed to purchase from the Corporation, and the Corporation agreed to sell to such Investors, shares of the Corporation’s Series D Convertible
Preferred Stock, par value $0.001 per share (the “Series D Preferred”); and 
 WHEREAS, the Prior Agreement permits the
Corporation and the record or beneficial Investors owning at least two-thirds (2/3) of the issued and outstanding shares of Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred”), to amend
the Prior Agreement; 
 WHEREAS, as a condition to the consummation of the transactions contemplated by the Series D Purchase Agreement, the
undersigned Investors, who are the record and beneficial Investors of at two-thirds (2/3) of the shares of Series C Preferred outstanding as of the date hereof, and the Corporation desire to amend and restate the Prior Agreement in its entirety
as set forth herein, to provide for the future voting of the Investors’ shares of Capital Stock and to set forth their respective rights and obligations relating to certain transfers of such shares, in each case as set forth herein with the
intention that this Agreement shall become effective concurrently with the Initial Closing. 
 AGREEMENT 

NOW THEREFORE, in consideration of the foregoing and of the mutual promises and covenants contained herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 
 SECTION 1.
Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 
 “Additional
Senior Preferred Director” shall have the meaning set forth in Section 4.1(a)(i)(B). 

 “Adversely Affected Investor” shall have the meaning set forth in
Section 6.4. 
 “Affiliate” shall mean, with respect to any Investor, any person or entity controlling, controlled by
or under common control with such Investor, and (i) with respect to vSpring SBIC, L.P., shall include any affiliate of vSpring Capital, LLC, (ii) with respect to Wasatch Venture Fund III, L.L.C., shall include any venture capital fund
managed by the general partners of Wasatch Venture Fund III, L.L.C., (iii) with respect to NMSIC Co-Investment Fund, L.P., shall include any affiliate of Sun Mountain Capital Partners, LLC, (iv) with respect to CCP/Exagen, L.P., shall
include Hunt Holdings L.P., and (v) with respect to Tullis-Dickerson Capital Focus III, L.P., shall include any pooled investment vehicle managed by Tullis-Dickerson and Co., Inc., or any of its affiliates. 

“Agreement” shall mean this Fourth Amended and Restated Stockholders’ Agreement, as the same may be amended from time to
time. 
 “Approved Action” shall have the meaning set forth in Section 6.1. 

“Board” shall mean the Board of Directors of the Corporation. 

“Capital Stock” shall mean the Common Stock and Preferred Stock. 

“CCP/Hunt” shall have the meaning set forth in Section 4.1(a)(i)(C). 

“CCP/Hunt Director” shall have the meaning set forth in Section 4.1(a)(i)(C). 

“Certificate” shall mean the Fourteenth Amended and Restated Certificate of Incorporation of the Corporation, as the same may
be amended from time to time. 
 “Common Director” shall have the meaning set forth in Section 4.1(a)(ii). 

“Common Stock” shall mean the Corporation’s common stock, $0.001 par value per share. 

“Co-Sale Investor” shall have the meaning set forth in Section 3.1. 

“Corporation” shall mean Exagen Diagnostics, Inc., a Delaware corporation, its successors and assigns. 

“Deemed Liquidation Event” shall have the meaning set forth in Section 5.1. 

“Electing Investor” shall have the meaning set forth in Section 2.2. 

“Equity Securities” shall mean, with respect to any Investor, any of the following that is now owned or that is hereinafter
acquired: (i) any Common Stock, Preferred Stock or other class or series of capital stock of the Company; (ii) any security convertible, with or without consideration, into any Common Stock, Preferred Stock or other class or series of
capital stock of the Company; (iii) any security carrying any warrant or right to subscribe for or purchase shares of any class or series of capital stock of the Company; and (iv) any warrant,

  
 -2- 

 
note, right, option or other derivative security which provides the right to subscribe for or purchase any stock or securities of the types listed in any of clauses (i), (ii), or
(iii) above. 
 “Excluded Securities” shall mean Common Stock issued or issuable (a) pursuant to the Series D
Purchase Agreement, (b) upon conversion of the Preferred Stock, (c) to officers, directors or employees of, or consultants to, the Corporation pursuant to any stock option, incentive, bonus or compensation program approved by the Board or
such other arrangements, contracts, or plans as are recommended by management and approved by the Board, (d) by way of dividend or other distribution on shares of Preferred Stock or by way of distribution on shares of Common Stock or Preferred
Stock pursuant to stock splits, recapitalizations and similar transactions, (e) upon exercise of warrants to purchase shares of Preferred Stock or Common Stock, (f) in a transaction with respect to which the holders of at least 60% of the
then outstanding shares of Senior Preferred, voting together as a single class, have waived their rights under Section 2 hereof, (g) in connection with a business acquisition of or by the Corporation, (h) pursuant to equipment lease
financings or bank credit arrangements approved by the Board, (i) for charitable purposes approved by the Board, or (j) as part of a corporate partnering transaction approved by the Board. 

“Financing Securities” shall have the meaning set forth in Section 2.1. 

“Independent Directors” shall have the meaning set forth in Section 4.1(a)(iii). 

“Major Investor” and “Major Investors” shall have the meaning set forth in Section 2.1. 

“Non-electing Investor” shall have the meaning set forth in Section 2.2. 

“Notice of Acceptance” shall have the meaning set forth in Section 2.2. 

“Offer” shall have the meaning set forth in Section 2.1. 

“Option” shall mean any security convertible into, or exchangeable or exercisable for, shares of Common Stock. 

“Preferred Stock” shall mean the Series A-3 Preferred, the Series B-3 Preferred, the Series C Preferred and the Series D
Preferred. 
 “Proposed Sale” shall have the meaning set forth in Section 5.3. 

“Proposed Transfer” shall mean any assignment, sale, offer to sell, pledge, mortgage, hypothecation, encumbrance, disposition
of or any other like transfer or encumbering of any Equity Securities proposed by any Investor. 
 “Proposed Transfer
Notice” shall mean written notice from an Investor setting forth the terms and conditions of a Proposed Transfer. 
 “pro
rata share” shall have the meaning set forth in Section 2.1. 

  
 -3- 

 “Remaining Securities” shall have the meaning set forth in Section 2.3.

 “Right of Co-Sale” shall mean the right, but not an obligation, of an Investor to participate in a Proposed Transfer on
the terms and conditions specified in the Proposed Transfer Notice. 
 “Sale of the Corporation” shall have the meaning set
forth in Section 5.1. 
 “Selling Investors” shall have the meaning set forth in Section 5.2. 

“Senior Preferred” shall mean the Series D Preferred, Series C Preferred and the Series B-3 Preferred. 

“Senior Preferred Directors” shall have the meaning set forth in Section 4.1(a)(i). 

“Series A-3 Preferred” shall mean the Corporation’s Series A-3 Preferred Stock, $0.001 par value per share. 

“Series B-3 Preferred” shall mean the Corporation’s Series B-3 Preferred Stock, $0.001 par value per share. 

“Series C Preferred” shall have the meaning set forth in the Recitals. 

“Series D Preferred” shall have the meaning set forth in the Recitals. 

“Series D Purchase Agreement” shall have the meaning set forth in the Recitals. 

“Stock Sale” shall have the meaning set forth in Section 5.1. 

“Sun Mountain” shall have the meaning set forth in Section 4.1(a)(i)(A). 

“Sun Mountain Director” shall have the meaning set forth in Section 4.1(a)(i)(A). 

“Transferring Investor” shall have the meaning set forth in Section 3.1. 

“Tullis” shall have the meaning set forth in Section 4.1(a)(i)(B). 

“Tullis Director” shall have the meaning set forth in Section 4.1(a)(i)(B). 

“Vote” shall have the meaning set forth in Section 4.1. 

“Voting Securities” shall mean, with respect to an Investor, (i) all Equity Securities and all other shares of capital
stock and other securities of the Company now or hereafter owned of record, or beneficially, by such Investor, and (ii) all other Equity Securities and other shares of capital stock and other securities over which the Investor has voting
control. 

  
 -4- 

 SECTION 2. Preemptive Rights. 

2.1. Except for Excluded Securities, the Corporation shall not issue, sell or exchange, agree to issue, sell or exchange, or reserve or set
aside for issuance, sale or exchange, (i) any shares of Common Stock, (ii) any other equity security of the Corporation, (iii) any debt security of the Corporation which by its terms is convertible into or exchangeable for, with or
without consideration, any equity security of the Corporation, (iv) any security of the Corporation that is a combination of debt and equity or (v) any security convertible into, or exchangeable or exercisable for, shares of Common Stock,
or warrant or other right to subscribe for, purchase or otherwise acquire any equity security or any such debt security of the type described in clause (iii) or (iv) above of the Corporation (collectively, the “Financing
Securities”) unless in each case the Corporation shall have first offered to sell to each Investor then holding at least 2,000,000 shares in the aggregate of Series D Preferred or Series C Preferred (subject to appropriate and proportionate
adjustment for any stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to, such shares) (or an equivalent amount of Common Stock issued upon conversion thereof) (each, a
“Major Investor” and collectively, the “Major Investors”) its pro-rata share of the Financing Securities, at a price and on such other terms as the Corporation proposes to offer such Financing Securities to other
parties and which shall have been specified by the Corporation in writing (an “Offer”) delivered to the Major Investors, which Offer by its terms shall remain open and irrevocable for a period of fifteen (15) days from the date
the Offer is received by the Major Investors (or, if later, within five (5) days after the giving of any written notice of a material change in such Offer). As used in this Section 2(a), a Major Investor’s “pro-rata
share” shall be that amount of the Financing Securities that equals (x) the aggregate amount of Financing Securities to be issued, sold or exchanged, multiplied by (y) a fraction (A) the numerator of which is the number of
shares of Common Stock issued or issuable upon the conversion of all shares of Preferred Stock held by such Major Investor immediately prior to the Offer and (B) the denominator of which is the number of shares of Common Stock issued or
issuable upon the conversion of all shares of Preferred Stock held by all Major Investors immediately prior to the Offer. The Offer will specify (i) the aggregate amount of Financing Securities to be issued, sold or exchanged, (ii) the
calculation of the Major Investor’s pro rata share and (iii) the number of shares, principal amount or the like of the Financing Securities which such Major Investor may purchase. 

2.2. Notice of a Major Investor’s intention to accept, in whole or in part, an Offer shall be evidenced by a writing signed by the Major
Investor and delivered to the Corporation at or prior to the end of the 15-day period commencing with the date the Offer is received by the Major Investor (or, if later, within 5 days after the giving of any written notice of a material change in
such Offer), setting forth such portion (specifying number of shares, principal amount or the like) of the Financing Securities as the Major Investor elects to purchase (the “Notice of Acceptance”). If a Major Investor elects to
purchase its full pro rata share of Financing Securities (each, an “Electing Investor”), then such Electing Investor shall have a right of over-allotment such that if any other Major Investor fails to purchase its pro rata share
(the “Non-electing Investor”), such Electing Investor may purchase, on a pro rata basis with other Electing Investors, the Non-electing Investor’s pro rata share. 

  
 -5- 

 2.3. The Corporation shall have 180 days from the expiration of the foregoing 15-day period to
sell all or any part of such Financing Securities as to which a Notice of Acceptance has not been given by the Major Investors (the “Remaining Securities”) to any other persons or entities, but only upon terms and conditions in all
material respects, including without limitation, per share price and interest rates, which are no more favorable, in the aggregate, to such other persons or entities or less favorable to the Corporation than those set forth in the Offer. Upon the
closing of the sale to such other persons or entities of all or any part of the Remaining Securities, which shall include payment of the purchase price to the Corporation in accordance with the terms of the Offer, if the Major Investor has timely
submitted a Notice of Acceptance, it shall purchase from the Corporation, and the Corporation shall sell to the Major Investor, the Financing Securities in respect of which a Notice of Acceptance was delivered to the Corporation by the Preferred
Investor, at the terms specified in the Offer. The purchase by the Major Investor of any Financing Securities is subject in all cases to the preparation, execution and delivery by the Corporation and the Major Investor of a purchase agreement and
other customary documentation relating to such Financing Securities as is reasonably satisfactory in form and substance to the Preferred Investor and its counsel. 

2.4. After the expiration of the 180-day period referred to in Section 2.2, any Financing Securities not purchased by the Major Investors
or by a person or entity in accordance with Section 2.2 may not be sold or otherwise disposed of until they are again offered to the Preferred Investors under the procedures specified in Sections 2.1, 2.2 and 2.2 hereof. 

2.5. Each Major Investor may assign its rights under this Section 2 to its Affiliates. 

SECTION 3. Right of Co-Sale. 

3.1. If any Investor proposes to engage in a Proposed Transfer (“Transferring Investor”), such Investor shall provide to each
Investor who owns Series D Preferred or Series C Preferred (each, a “Co-Sale Investor”) a Proposed Transfer Notice. Each Co-Sale Investor may elect to exercise its Right of Co-Sale and participate in the Proposed Transfer on a pro
rata basis as set forth below and otherwise on the same terms and conditions specified in the Proposed Transfer Notice (provided that if the Proposed Transfer is a transfer of Common Stock and a Co-Sale Investor wishes to sell Preferred Stock, the
price set forth in the Proposed Transfer Notice shall be appropriately adjusted based on the conversion ratio of the Preferred Stock into Common Stock). Each Co-Sale Investor who desires to exercise its Right of Co-Sale must give the Transferring
Investor written notice to that effect within fifteen (15) days after receipt of the Proposed Transfer Notice, and upon giving such notice, such Investor shall be deemed to have effectively exercised the Right of Co-Sale. 

3.2. Each Co-Sale Investor who timely exercises such Co-Sale Investor’s Right of Co-Sale by delivering the written notice provided for
above in Section 3.1 may include in the Proposed Transfer all or any part of such Co-Sale Investor’s Capital Stock equal to the product obtained by multiplying (i) the aggregate number of shares of Capital Stock subject to the
Proposed Transfer by (ii) a fraction, (A) the numerator of which is the number of shares of Common Stock issued or issuable upon the conversion of all shares of Preferred Stock 

  
 -6- 

 
held by such Co-Sale Investor immediately before consummation of the Proposed Transfer and (B) the denominator of which is the total number of shares of Common Stock issued or issuable upon
the conversion of all shares of Preferred Stock held by all Co-Sale Investors immediately before consummation of the Proposed Transfer, plus the number of shares of Common Stock and shares of Common Stock issuable upon the conversion of all shares
of Preferred Stock held by the Transferring Investor immediately before consummation of the Proposed Transfer. To the extent one or more Co-Sale Investors exercise a Right of Co-Sale, the number of shares of Capital Stock that the Transferring
Investor may sell in the Proposed Transfer shall be correspondingly reduced. 
 3.3. Each Co-Sale Investor who timely exercises its Right of
Co-Sale shall deliver to the Transferring Investor, no later than fifteen (15) days after such Co-Sale Investor’s exercise of the Right of Co-Sale, one or more stock certificates, properly endorsed for transfer to the prospective
transferee, representing the number of shares of Common Stock that such Co-Sale Investor elects to include in the Proposed Transfer or the number of shares of Preferred Stock that is at such time convertible into the number of shares of Common Stock
that such Co-Sale Investor elects to include in the Proposed Transfer; provided, however, that if the prospective transferee objects to the delivery of convertible Preferred Stock in lieu of Common Stock, such Co-Sale Investor shall first convert
the Preferred Stock into Common Stock and deliver Common Stock as provided above. The Corporation agrees to make any such conversion concurrent with and contingent upon the actual transfer of such shares to the prospective transferee. 

3.4. Each stock certificate that a Co-Sale Investor delivers to the Transferring Investor pursuant to this Section 3 will be transferred
to the prospective transferee against payment therefor in consummation of the sale thereof pursuant to the terms and conditions specified in the Proposed Transfer Notice and the purchase and sale agreement, and the Transferring Investor shall
concurrently therewith remit or direct payment to each Co-Sale Investor of the portion of the sale proceeds to which such Co-Sale Investor is entitled by reason of its participation in such sale. If any prospective transferee refuses to purchase
securities subject to the Right of Co-Sale from any Co-Sale Investor exercising its Right of Co-Sale hereunder, none of the Co-Sale Investors or the Transferring Investor may sell any Capital Stock to such prospective transferee unless and until,
simultaneously with such sale, such Transferring Investor purchases all Capital Stock subject to the Right of Co-Sale from the Co-Sale Investor exercising its Right of Co-Sale on the same terms and conditions as set forth in the Proposed Transfer
Notice. 
 3.5. If any Proposed Transfer is not consummated within sixty (60) days after receipt of the Proposed Transfer Notice, the
Transferring Investor(s) proposing the Proposed Transfer, may not sell any Capital Stock unless they first comply in full with each provision of this Section 3. The exercise or election not to exercise any right by a Co-Sale Investor hereunder
shall not adversely affect such Co-Sale Investor’s right to participate in any other sales of Capital Stock subject to Section 3. 

  
 -7- 

 SECTION 4. Board of Directors. 

4.1. Composition. Each Investor shall hold all Voting Securities subject to, and shall vote or consent pursuant to an action by written
consent of the stockholders of the Company (“Vote”) such Voting Securities in accordance with, the provisions of this Agreement. 

(a) Election of Directors. 

(i) Senior Preferred Directors. On all matters relating to the election of the class of directors designated in the Certificate as
being elected only by the holders of Senior Preferred, the Investors holding Senior Preferred Stock, acting together as a single class, shall Vote all of their respective Voting Securities so as to elect as a member of the Board three
(3) individuals (the “Senior Preferred Directors”) nominated as follows: 
 (A) For so long as NMSIC Co-Investment
Fund, L.P. or Affiliates thereof (“Sun Mountain”) owns any shares of Senior Preferred or Common Stock, one (1) director designated by Sun Mountain (the “Sun Mountain Director”). The Sun Mountain Director shall
initially be Brian Birk. 
 (B) For so long as Tullis-Dickerson Capital Focus III, L.P. or Affiliates thereof (“Tullis”)
owns any shares of Senior Preferred or Common Stock, one (1) director designated by Tullis (the “Tullis Director”). 

(C) For so long as CCP/Exagen, L.P. or Affiliates thereof (“CCP/Hunt”) owns any shares of Senior Preferred or Common Stock,
one (1) director designated by CCP/Hunt (the “CCP/Hunt Director”). The CCP/Hunt Director shall initially be Ebetuel Pallares. 

(D) If either or both of Sun Mountain or CCP/Hunt is no longer entitled to designate the Sun Mountain Director or the CCP/Hunt Director, as
applicable, then the director(s) to be elected by the holders of the issued and outstanding shares of Senior Preferred in lieu of the Sun Mountain Director or the CCP/Hunt Director shall be reasonably acceptable to Tullis for so long as Tullis is
entitled to designate a Senior Preferred Director pursuant to Section 4.1(a)(i)(B). 
 (ii) Common Director. On all matters
relating to the election of the class of directors designated in the Certificate as being elected only by the holders of Common Stock, the Investors holding Common Stock shall Vote all of their respective Voting Securities so as to elect one
(1) director who shall be the Company’s then-current Chief Executive Officer (the “Common Director”). The Common Director initially shall be Ron Rocca. 

(iii) Independent Directors. On all matters relating to the election of members of the Board other than the Senior Preferred Directors
and the Common Director, the Investors shall Vote all of their respective Voting Securities so as to elect two (2) directors nominated by Senior Preferred Directors, both of whom shall be independent and not

  
 -8- 

 
an Affiliate of the Company or any Investor and who shall have industry experience (the “Independent Directors”). The Independent Directors initially shall be Samuel Riccitelli
and Michael Walsh. 
 (iv) Additional Director. On all matters relating to the election of members of the Board other than the
Senior Preferred Directors, the Common Director and the Independent Directors, the Investors agree to Vote all of their respective Voting Securities so as to elect one (1) director designated by the holders of at least sixty percent
(60%) of the then issued and outstanding shares of Senior Preferred Stock. 
 The obligation to Vote shares in accordance with this Section 3
shall be specifically applicable to and enforceable against any transferees of the parties hereto. 
 (b) Vacancies; Removal. Each
of the directors elected pursuant to Section 4 shall hold office, subject to his or her resignation or earlier removal from the Board in accordance with the following sentence, in accordance with the Certificate, the Bylaws of the
Corporation and applicable law, until his or her successors shall have been elected and shall have been duly qualified. No Investor shall vote to remove any director elected pursuant to this Section 4, or to fill any vacancy created by
the resignation or removal of a director elected pursuant to this Section 4, unless such action shall have been approved by the Investors entitled to nominate and elect such director in accordance with the provisions of the Certificate
and this Section 4. 
 (c) Meetings. The Board shall hold meetings no less frequently than quarterly as determined by a
majority of the Board. 
 (d) Committees of the Board. The Corporation shall establish and maintain a compensation committee and an
audit committee and may also form an executive committee or any other special committee of the Board. Each of such committees shall have at least one (1) of the Senior Preferred Directors as a member of such committees. 

(e) Insurance. The Corporation shall obtain and maintain directors’ and officers’ liability insurance in reasonable amounts
from established and reputable insurers. 
 (f) Size of Board. Each Investor shall take all actions, do all things and execute and
deliver all documents, including, without limitation, approving an amendment to the Corporation’s Bylaws, and shall cause the Corporation to do the same, as may be necessary to ensure that the number of directors authorized and constituting the
entire Board shall be seven (7), subject to increase or decrease in accordance with the terms of the Certificate and pursuant hereto. 

(g) No Liability. No Investor, nor any Affiliate thereof, shall have any liability as a result of nominating a person for election as
a director, for any act or omission by such designated person in his or her capacity as a director of the Corporation, or as a result of voting for any such nominee in accordance with the provisions of this Agreement. 

  
 -9- 

 (h) Irrevocable Proxy. Each party to this Agreement hereby grants to a stockholder
appointed by the Board, with full power of substitution, an irrevocable proxy with respect to the matters set forth herein, including, without limitation, the election of directors to the Board in accordance with Section 4.1(a) and
Section 4.1(b) hereof, and hereby authorizes such proxy to represent and to Vote, if and only if the party (i) fails to Vote, or (ii) attempts to Vote, in a manner which is inconsistent with the terms of this Agreement, all of such
party’s Voting Securities in favor of the election of directors to the Board determined pursuant to and in accordance with the terms and provisions of this Agreement. The proxy granted pursuant to the immediately preceding sentence is given in
consideration of the agreements and covenants of the parties in connection with the transactions contemplated by this Agreement and, as such, is coupled with an interest and shall be irrevocable unless and until this Agreement terminates pursuant to
the terms hereof. 
 SECTION 5. Drag-Along Right. 

5.1. A “Sale of the Corporation” shall mean either (a) a transaction or series of related transactions in which a
person, or a group of related persons, acquires from stockholders of the Corporation shares representing more than fifty percent (50%) of the outstanding voting power of the Corporation (a “Stock Sale”) or (b) a
transaction that is deemed to be a liquidation under Section 3.2 of the Certificate (a “Deemed Liquidation Event”). 

5.2. In the event that (i) Investors holding at least a majority of the shares of Series C Preferred or Series D Preferred then
outstanding (collectively, the “Selling Investors”) and (ii) the Board of Directors approve a Sale of the Corporation in writing, specifying that this Section 5 shall apply to such transaction, then each Investor hereby
agrees: 
 (a) if such transaction requires stockholder approval, with respect to all Capital Stock that such Investor owns or over which
such Investor exercises voting power, to vote, in person, by proxy, or by written consent, all Capital Stock in favor of, and adopt, such Sale of the Corporation (together with any related amendment to the Restated Certificate of Incorporation
required in order implement such Sale of the Corporation) and to vote in opposition to any and all other proposals that could delay or impair the ability of the Corporation to consummate such Sale of the Corporation; 

(b) if such transaction is a Stock Sale, to sell the same proportion of shares of capital stock of the Corporation beneficially held by such
Investor as is being sold by the Selling Investors to the person to whom the Selling Investors propose to sell their Capital Stock, and, except as permitted in Section 5.2(c) below, on the same terms and conditions as the Selling Investors;

 (c) to execute and deliver all related documentation and take such other action in support of the Sale of the Corporation as shall
reasonably be requested by the Corporation or the Selling Investors in order to carry out the terms and provisions of this Section 5, including without limitation executing and delivering instruments of conveyance and transfer, and any purchase
agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer 

  
 -10- 

 
(free and clear of impermissible liens, claims and encumbrances) and any similar or related documents; 

(d) not to deposit, and to cause their Affiliates not to deposit, except as provided in this Agreement, any Capital Stock owned by such
Investor or Affiliate in a voting trust or subject any Capital Stock to any arrangement or agreement with respect to the voting of such Capital Stock, unless specifically requested to do so by the acquiror in connection with the Sale of the
Corporation; 
 (e) to refrain from exercising any dissenters’ rights or rights of appraisal under applicable law at any time with
respect to such Sale of the Corporation; and 
 (f) if the consideration to be paid in exchange for the Capital Stock pursuant to this
Section 5 includes any securities and due receipt thereof by any Investor would require under applicable law (x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such
securities or (y) the provision to any Investor of any information other than information as a prudent issuer would generally furnish in an offering made solely to “accredited investors” as defined in Regulation D promulgated under
the Securities Act of 1933, as amended, the Corporation may cause to be paid to any such Investor in lieu thereof, against surrender of the Capital Stock which would have otherwise been sold by such Investor, an amount in cash equal to the fair
value (as determined in good faith by the Corporation) of the securities which such Investor would otherwise receive as of the date of the issuance of such securities in exchange for the Capital Stock. 

5.3. Notwithstanding the foregoing, an Investor will not be required to comply with Section 5.2(b) above in connection with any proposed
Sale of the Corporation (the “Proposed Sale”) unless: 
 (a) any representations and warranties to be made by such
Investor in connection with the Proposed Sale are limited to representations and warranties related to authority, ownership and the ability to convey title to such Capital Stock, including but not limited to representations and warranties that
(a) the Investor holds all right, title and interest in and to the Capital Stock such Investor purports to hold, free and clear of all liens and encumbrances, (b) the obligations of the Investor in connection with the transaction have been
duly authorized, if applicable, (c) the documents to be entered into by the Investor have been duly executed by the Investor and delivered to the acquirer and are enforceable against the Investor in accordance with their respective terms and
(d) neither the execution and delivery of documents to be entered into in connection with the transaction, nor the performance of the Investor’s obligations thereunder, will cause a breach or violation of the terms of any agreement, law or
judgment, order or decree of any court or governmental agency; 
 (b) the Investor shall not be liable for the inaccuracy of any
representation or warranty made by any other person in connection with the Proposed Sale, other than the Corporation (except to the extent that funds may be paid out of an escrow established to cover breach of representations, warranties and
covenants of the Corporation as well as breach by any Investor of any of identical representations, warranties and covenants provided by all Investors); 

  
 -11- 

 (c) the liability for indemnification, if any, of such Investor in the Proposed Sale and for the
inaccuracy of any representations and warranties made by the Corporation or its Investors in connection with such Proposed Sale, is several and not joint with any other Person (except to the extent that funds may be paid out of an escrow established
to cover breach of representations, warranties and covenants of the Corporation as well as breach by any Investor of any of identical representations, warranties and covenants provided by all Investors), and is pro rata in proportion to, and does
not exceed, the amount of consideration paid to such Investor in connection with such Proposed Sale; 
 (d) liability shall be limited to
such Investor’s applicable share (determined based on the respective proceeds payable to each Investor in connection with such Proposed Sale in accordance with the provisions of the Corporation’s Restated Certificate of Incorporation) of a
negotiated aggregate indemnification amount that applies equally to all Investors but that in no event exceeds the amount of consideration otherwise payable to such Investor in connection with such Proposed Sale, except with respect to claims
related to fraud by such Investor, the liability for which need not be limited as to such Investor; 
 (e) upon the consummation of the
Proposed Sale, (i) each holder of each class or series of the Corporation’s stock will receive the same form of consideration for their shares of such class or series as is received by other holders in respect of their shares of such same
class or series of stock, (ii) each holder of a series of Preferred Stock will receive the same amount of consideration per share of such series of Preferred Stock as is received by other holders in respect of their shares of such same series,
(iii) each holder of Common Stock will receive the same amount of consideration per share of Common Stock as is received by other holders in respect of their shares of Common Stock, and (iv) the aggregate consideration receivable by all
holders of the Preferred Stock and Common Stock shall be allocated among the holders of Preferred Stock and Common Stock on the basis of the relative liquidation preferences to which the holders of each respective series of Preferred Stock and the
holders of Common Stock are entitled in a Deemed Liquidation Event (assuming for this purpose that the Proposed Sale is a Deemed Liquidation Event) in accordance with the Corporation’s Restated Certificate of Incorporation in effect immediately
prior to the Proposed Sale; provided, however, that, notwithstanding the foregoing, if the consideration to be paid in exchange for an Investor’s Capital Stock pursuant to this 5.2(e) includes any securities and due receipt thereof by
any Investor would require under applicable law (x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities or (y) the provision to any Investor of any
information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited investors” as defined in Regulation D promulgated under the Securities Act of 1933, as amended, the Corporation
may cause to be paid to any such Investor in lieu thereof, against surrender of the Investor s Capital Stock which would have otherwise been sold by such Investor, an amount in cash equal to the fair value (as determined in good faith by the
Corporation) of the securities which such Investor would otherwise receive as of the date of the issuance of such securities in exchange for the Investor’s Capital Stock; and 

(f) subject to the immediately preceding paragraph, requiring the same form of consideration to be available to the holders of any single
class or series of capital stock, if any holders of any capital stock of the Corporation are given an option as to the 

  
 -12- 

 
form and amount of consideration to be received as a result of the Proposed Sale, all holders of such capital stock will be given the same option; provided, however, that nothing in this
Section 5.2(f) shall entitle any holder to receive any form of consideration that such holder would be ineligible to receive as a result of such holder’s failure to satisfy any condition, requirement or limitation that is generally
applicable to the Corporation’s Investors. 
 5.4. Proxy. Each Investor hereby grants to the Selling Investors (i) an
irrevocable proxy, coupled with an interest, to Vote all Voting Securities owned by such Investor, and (ii) an irrevocable power of attorney, which is coupled with an interest, to take such other actions, in each case to the extent necessary to
carry out the provisions of this Section 5 in the event of any breach by such Investor of its obligations hereunder. 
 SECTION 6.
Miscellaneous. 
 6.1. Voting Agreement. In the event that the taking of any one or more of the actions listed in Article Fourth,
Section 7 of the Certificate (an “Approved Action”) would require a separate vote by the holders of either of the Series A-3 Preferred or the Series B-3 Preferred under Section 242(b)(2) of the General Corporation Law of
the State of Delaware, then, in such event, each holder of Series A-3 Preferred and Series B-3 Preferred, as applicable, hereby agrees, with respect to all shares of Series A-3 Preferred or Series B-3 Preferred over which he, she or it exercises
voting or dispositive authority, to Vote all of such Series A-3 Preferred or Series B-3 Preferred in favor of the Approved Action if the holders of at least 60% of the then outstanding Series D Preferred and Series C Preferred, voting together as a
single class, Vote to approve the taking of such Approved Action. 
 6.2. Assignment of Rights. This Agreement and the rights and
obligations of the parties hereunder shall inure to the benefit of, and be binding upon, the parties’ respective successors, assigns and legal representatives; provided, however, that the rights of the Investors hereunder are only
assignable to a assignee or transferee (i) who acquires all of the securities of the Corporation purchased by an Investor or at least ten percent (10%) of such class and series of securities or (ii) who is a partner or retired partner
of a partnership, and it shall be a requirement of such transfer that such assignee shall then become a party to this Agreement. 
 6.3.
Term. This Agreement shall terminate upon the earlier of (i) the closing of a firmly underwritten initial public offering of the Corporation’s Common Stock or (ii) the acquisition of the Corporation by another entity by means
of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation) or a sale of all or substantially all of the assets of the Corporation, unless the Corporation’s stockholders of
record as constituted immediately prior to such acquisition or sale will, immediately after such acquisition or sale (by virtue of securities issued as consideration for the Corporation’s acquisition or sale or otherwise) hold at least 50% of
the voting power of the surviving or acquiring entity. 
 6.4. Waivers and Amendments. This Agreement may not be amended, modified or
waived at any time, unless such amendment, modification or waiver is first approved in writing by (a) the Investors owning at least two-thirds (2/3) of the issued and outstanding shares of Series D Preferred, (b) the Investors owning
at least two-thirds (2/3) of the issued and 

  
 -13- 

 
outstanding shares of Series C Preferred, and (c) the Corporation; provided, however, that (i) if any amendment, modification or waiver would apply to a Holder (each, an
“Adversely Affected Investor”) in a fashion different than how such amendment, modification or waiver applies to all Investors, then such amendment, modification or waiver shall not be effective as to such Adversely Affected
Investor unless consented to by such Adversely Affected Investor, (ii) any amendment, modification or waiver of Section 4.1(a)(i)(A) or of this clause (ii) shall require shall require the approval of NMSIC Co-Investment Fund, L.P. if
at the time of such amendment, modification or waiver, NMSIC Co-Investment Fund, L.P. is entitled to designate a Senior Preferred Director pursuant to Section 4.1(a)(i)(A), (iii) any amendment, modification or waiver of
Section 4.1(a)(i)(B), Section 4.1)(a)(i)(D) or of this clause (iii) shall require shall require the approval of Tullis-Dickerson Capital Focus III, L.P. if at the time of such amendment, modification or waiver, Tullis-Dickerson
Capital Focus III, L.P. is entitled to designate a Senior Preferred Director pursuant to Section 4.1(a)(i)(B), and (iv) any amendment, modification or waiver of Section 4.1(a)(i)(C) or of this clause (iv) shall require shall
require the approval of CCP/Exagen, L.P. if at the time of such amendment, modification or waiver, CCP/Hunt is entitled to designate a Senior Preferred Director pursuant to Section 4.1(a)(i)(C). Any amendment, modification or waiver so effected
shall be binding upon the Corporation, each of the parties hereto and any assignee of any such party. In addition, the Company may waive performance of any obligation owing to it, as to some or all of the Investors, or agree to accept alternatives
to such performance, without obtaining the consent of any Investor. No waiver of any breach of this Agreement extended by any party hereto to any other party shall be construed as a waiver of any rights or remedies of any other party hereto or with
respect to any subsequent breach 
 6.5. Governing Law. This Agreement shall be governed in all respects by the laws of the State of
Delaware, without regards to conflict of laws principles. 
 6.6. Effectiveness; Entire Agreement. This Agreement shall become
effective concurrently with the consummation of the purchase and sale of the Series D Preferred Stock under the Series D Purchase Agreement at the Initial Closing. This Agreement and the other documents delivered in connection herewith constitute
the full and entire understanding of the parties with regard to the subjects hereof and thereof, and this Agreement shall supersede and cancel all prior agreements between the parties hereto with regard to the subject matter hereof, including the
Prior Agreement. 
 6.7. Notices, etc. All notices and other communications required or permitted hereunder (each, a
“Notice”) shall be in writing and shall be delivered by overnight courier service or mailed by first class mail, postage prepaid, certified or registered mail, return receipt requested, addressed (a) if to an Investor, at such
party’s address as set forth in the Corporation’s records, or at such other address as such party shall have furnished to the Corporation in writing or (b) if to the Corporation, to it at the address set forth on the
Corporation’s signature page hereto or other address as the Corporation shall have furnished to the Investor in writing. All Notices shall be deemed effectively given: (x) upon personal delivery to the party to be notified, (y) three
(3) days after having been sent by first class mail, postage prepaid, certified or registered mail, return receipt requested and (z) one (1) day after deposit with an overnight courier service. 

  
 -14- 

 6.8. Severability. In case any provision of this Agreement shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby. 

6.9. Title and Subtitles. The titles of the sections and subsections of this Agreement are for convenience of reference only and are
not to be considered in construing this Agreement. 
 6.10. Attorneys’ Fees. If any action at law or in equity is necessary to
enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and disbursements in addition to any other relief to which such party may be entitled. 

6.11. Counterparts; Execution by Facsimile Signature. This Agreement may be executed in any number of counterparts, each of which shall
be an original, but all of which together shall constitute one instrument. This Agreement may be executed by facsimile signature(s) which shall be binding on the party delivering same, to be followed by delivery of originally executed signature
pages. 
 6.12. Aggregation of Stock. All shares of Preferred Stock and Common Stock of the Corporation held or acquired by
affiliated entities or persons shall be aggregated for the purpose of determining the availability of any rights under this Agreement. 

6.13. Additional Investors. Notwithstanding anything to the contrary contained herein, if the Corporation shall issue additional shares
of Preferred Stock from time to time, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and shall be deemed an
“Investor” and a party hereunder. 
 6.14. Specific Performance. The parties hereto hereby declare that it is impossible to
measure in money the damages which will accrue to a party hereto or to their heirs, personal representatives, successors or assigns by reason of the failure of a party to perform any of the obligations under this Agreement and agree that the terms
of this Agreement shall be specifically enforceable. If any party hereto or such party’s heirs, personal representatives, or assigns institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such
action or proceeding is brought hereby waives the claim or defense therein that such party or such personal representative has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such
remedy at law exists. 
 *  *  *  *  *  *  * 

  
 -15- 

 IN WITNESS WHEREOF, the parties hereto have executed this Fourth Amended and Restated
Stockholders Agreement as of the date first above written. 
  

			
	CORPORATION:
	
	EXAGEN DIAGNOSTICS, INC.
		
	By:	 	

		 	  

	Name:	 	Ron Rocca
	Title:	 	President and Chief Executive Officer
	
	INVESTORS:
	
	WASATCH VENTURE FUND III, LLC
		
	By:	 	  

	Name:	 	Kent Madsen
	Title:	 	Managing Director
	
	WASATCH NEW MEXICO FUND, LLC
		
	By:	 	  

	Name:	 	Kent Madsen
	Title:	 	Managing Director
	
	VSPRING SBIC, L.P.
		
	By:	 	vSpring SBIC Management, L.L.C., its
		 	general partner
		
	By:	 	  

	Name:	 	Dinesh Patel
	Title:	 	Managing Director

 [Signature Page to Fourth Amended and Restated Stockholders Agreement] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fourth Amended and Restated
Stockholders Agreement as of the date first above written. 
  

			
	CORPORATION:
	
	EXAGEN DIAGNOSTICS, INC.
		
	By:	 	  

	Name:	 	Ron Rocca
	Title:	 	President and Chief Executive Officer
	
	INVESTORS:
	
	WASATCH VENTURE FUND III, LLC
		
	By:	 	

		 	  

	Name:	 	Kent Madsen
	Title:	 	Managing Director
	
	WASATCH NEW MEXICO FUND, LLC
		
	By:	 	

		 	  

	Name:	 	Kent Madsen
	Title:	 	Managing Director
	
	VSPRING SBIC, L.P.
		
	By:	 	vSpring SBIC Management, L.L.C., its general partner
		
	By:	 	  

	Name:	 	Dinesh Patel
	Title:	 	Managing Director

 [Signature Page to Fourth Amended and Restated Stockholders Agreement] 

 
			
	NMSIC CO-INVESTMENT FUND, L.P.
		
	By:	 	Sun Mountain Capital Partners LLC, its general partner
		
	By:	 	

		 	  

		 	Brian Birk, Managing Partner
		
	By:	 	

		 	  

		 	Sally Corning, Partner
	
	MESA VERDE VENTURE PARTNERS, L.P.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	JAMES J. SCHWARZ and JEANETTE M.
	SCHWARZ, CO-TRUSTEES OF THE
	SCHWARZ TRUST
		
	By	 	  

		 	James J. Schwarz
		
	By	 	  

		 	Jeanette M. Schwarz
	
	  

	LISA DAVIS
	
	NEW TECH I, L.P.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	QUATRO VENTURES, LLC

 [Signature Page to Fourth Amended and Restated Stockholders Agreement] 

 
			
	NMSIC CO-INVESTMENT FUND, L.P.
		
	By:	 	Sun Mountain Capital Partners LLC, its general partner
		
	By:	 	  

		 	Brian Birk, Managing Partner
		
	By:	 	  

		 	Sally Corning, Partner
	
	MESA VERDE VENTURE PARTNERS, L.P.
		
	By:	 	

		 	  

	Name:	 	DANIEL C. WOOD
	Title:	 	Member
	
	JAMES J. SCHWARZ and JEANETTE M.
	SCHWARZ, CO-TRUSTEES OF THE
	SCHWARZ TRUST
		
	By	 	  

		 	James J. Schwarz
		
	By	 	  

		 	Jeanette M. Schwarz
	
	  

	LISA DAVIS
	
	NEW TECH I, L.P.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	QUATRO VENTURES, LLC

 [Signature Page to Fourth Amended and Restated Stockholders Agreement] 

 
			
	By:	 	  

	Name:	 	
	Title:	 	
	
	  

	PAMELA J. SULLIVAN
	
	  

	THOMAS A. TUMOLILLO
	
	  

	RAY RADOSEVICH
	
	SOUTHWEST MEDICAL VENTURES, INC.
		
	By:	 	

		 	  

	Name:	 	Waneta C Tuttle
	Title:	 	President
	
	TULLIS-DICKERSON CAPITAL FOCUS III, L.P.
		
	By:	 	Tullis-Dickerson Partners III, L.L.C., its general partner
		
	By:	 	  

	Name:	 	James L.L. Tullis
	Title:	 	Manager
	
	BERGE G. HAGOPIAN AND MARY ANN
	HAGOPIAN, CO-TRUSTEES, HAGOPIAN
	FAMILY TRUST UA DTD 03/25/88

 
			
	By:	 	
		 	  

	Name:	 	
	Title:	 	
	
	     
	  

	PAMELA J. SULLIVAN
	
	     
	  

	 THOMAS A. TUMOLILLO

	
	     
	  

	RAY RADOSEVICH
	
	SOUTHWEST MEDICAL VENTURES, INC.
		
	By:	 	
		 	  

	Name:	 	
	Title:	 	
	
	TULLIS-DICKERSON CAPITAL FOCUS III, L.P.
		
	By:	 	Tullis-Dickerson Partners III, L.L.C., its
		 	general partner
		
	By:	 	

		 	  

	Name:	 	James L.L. Tullis
	Title:	 	Manager
	
	BERGE G. HAGOPIAN AND MARY ANN
	HAGOPIAN, CO-TRUSTEES, HAGOPIAN
	FAMILY TRUST UA DTD 03/25/88
		
	By:	 	
		 	  

		 	Berge K. Hagopian, Trustee

 [Signature Page to Fourth Amended and Restated Stockholders Agreement] 

 
			
	TIMOTHY M. PENNINGTON AND MELISSA
	PENNINGTON AS TRUSTEES OF THE
	PENNINGTON FAMILY REVOCABLE TRUST
	UA DATED MAY 23, 1984
		
	By:	 	
		 	  

		 	Timothy M. Pennington, Trustee
	
	ENDOCHOICE, INC.
		
	By:	 	
		 	  

	Name:	 	
	Title:	 	
	
	HUNT HOLDINGS LIMITED PARTNERSHIP
	By: HuntVest, LLC, its General Partner
	By: Hunt Guaranty Inc., its Sole Member
		
	By:	 	

		 	  

	Name:	 	Matthew D. Hunt
	Title:	 	Manager
	
	CCP/EXAGEN, L.P.
		
	By	 	  

	Name:	 	Ebetuel Pallares-Venegas
	Title:	 	Managing Partner
	
	VSPRING, L.P.
		
	By:	 	vSpring Management, LLC
		 	its General partner
		
	By	 	
		 	  

	Name:	 	Dinesh Patel
	Title:	 	Managing Director

 [Signature Page to Fourth Amended and Restated Stockholders Agreement] 

 
			
	VSPRING PARTNERS, L.P.
		
	By:	 	vSpring Management, LLC
		 	its General partner
		
	 By:
	 	
		 	  

	 Name:
	 	Dinesh Patel
	 Title:
	 	Managing Director
	
	GLENN HOLDINGS, L.P.
		
	By:	 	
		 	  

	 Name:
	 	
	 Title:
	 	

 [Signature Page to Fourth Amended and Restated Stockholders Agreement] 

 SCHEDULE A 

INVESTORS 
 Wasatch Venture Fund
III, LP 
 Wasatch New Mexico Fund, LLC 
 vSpring SBIC, L.P.

 vSpring, L.P. 
 vSpring Partners, L.P. 

NMSIC Co-Investment Fund, L.P. 
 NMSIC Focused, LLC 

James J. Schwarz and Jeanette M. Schwarz, Co-Trustees of the Schwarz Trust 

Jane Hillhouse 
 Lisa Davis 

New Tech I, L.P. 
 Pamela J. Sullivan and Thomas A. Tumolillo

 Quatro Ventures, LLC 
 Ray Radosevich 

Robert and Marcia Cates 
 Robert H. Nath 

Southwest Medical Ventures, Inc. 
 Sheryl A. Johnson 

John P. Alsobrook, II 
 Dale Olson 

Mesa Verde Venture Partners, L.P. 
 CCP/Exagen, L.P. 

Hunt Holdings L.P. 
 Tullis-Dickerson Capital Focus III, L.P.

 Berge K. Hagopian and Mary Ann Hagopian, Co-Trustees, Hagopian Family Trust UA DTD 03/25/88 

Timothy M. Pennington and Melissa J. Pennington as Trustees of the Pennington Family 

Revocable Trust UA Dated May 23, 1984 
 Endochoice, Inc.

  
 A-1 

 Glenn Holdings, L.P. 

  
 A-2EX-4.4

 Exhibit 4.4 

THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE,
AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT AND/OR APPLICABLE STATE SECURITIES LAWS, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY
SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED. 
 Warrant No. WP-11 

EXAGEN DIAGNOSTICS, INC. 

COMMON STOCK PURCHASE WARRANT 

THIS CERTIFIES that
                                         (the
“Holder”) is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after the date of this warrant (this “Warrant”) and on or prior to
                                   (the “Expiration Date”), but not
thereafter, to subscribe for and purchase from Exagen Diagnostics, Inc., a Delaware corporation (the
“Company”),                                     
    (                 ) shares of Common Stock in the Company (the “Shares”) at an exercise price of
$         per share (the “Exercise Price”). 
 1. Exercise of Warrant. 

(a) Unless earlier terminated under Section 7, the purchase rights represented by this Warrant to purchase Shares are exercisable, in
whole or in part, before the close of business on the Expiration Date, by the surrender of this Warrant and the Notice of Exercise annexed hereto duly executed at the principal executive office of the Company (or such other office or agency of the
Company as it may designate by notice in writing to the Holder at the address of the Holder appearing on the books of the Company), and upon payment of the Exercise Price of the Shares thereby purchased (by cash or by check or bank draft payable to
the order of the Company in an amount equal to the Exercise Price of the shares thereby purchased). 
 (b) Unless earlier terminated under
Section 7, in lieu of exercising this Warrant by payment of cash or check pursuant to Section 1(a), the Holder may elect to receive Shares equal to the value of this Warrant (or the portion thereof being exercised), by surrender of this
Warrant at the principal executive office of the Company, together with the Notice of Conversion annexed hereto, in which event the Company will issue to the Holder Shares in accordance with the following formula: 

									
		 	X	 	  =        	 	Y(A-B)	 	
		 		 		 	     A	 	

  

									
	Where,        	  	X	  	    =  	 	the number of Shares to be issued to Holder;
				
		  	Y	  	    =  	 	the number of Shares for which the Warrant is being exercised;
				
		  	A	  	    =  	 	the fair market value of one Share; and
				
		  	B	  	    =  	 	the Exercise Price.

 For purposes of this Section 1(b), the fair market value of a Share shall be the price per Share that the
Company could obtain from a willing buyer for Shares sold by the Company from authorized but unissued Shares, as such price shall be determined in good faith by the Company’s Board of Directors. If the Shares are traded on the over-the-counter
market or on an exchange, the fair market value of a Share shall be the average of the closing bid and asked prices of Shares quoted in the over-the-counter market in which the Shares are traded or the closing price quoted on any exchange on which
the Shares are listed, whichever is applicable, as published in the Western Edition of The Wall Street Journal for the ten (10) trading days prior to the date of determination of fair market value (or such shorter period of time during which
such stock was traded over-the-counter or on such exchange). 
 (c) As soon as practicable after the exercise of this Warrant in whole or in
part, and in any event within ten (10) days thereafter, the Company at its expense will cause to be issued in the name of, and delivered to, the Holder, or such other name as specified on the Notice of Exercise delivered to the Company: 

(i) a certificate or certificates for the number of Shares to which such Holder shall be entitled, and 

(ii) in case such exercise is in part only, a Warrant or Warrants (dated the date hereof) of like tenor, calling in the aggregate on the face
or faces thereof for the number of Shares equal (without giving effect to any adjustments therein) to the number of Shares called for on the face of this Warrant minus the number of such Shares purchased by the Holder upon such exercise as provide
in Sections 1(a) or (b) above. 
 2. Shares to be Fully Paid; Reservation of Shares. The Company covenants that all Shares which
may be issued upon the exercise of rights represented by this Warrant (together with all shares of Common Stock issuable upon conversion of such Shares) will, upon issuance, be duly authorized, validly issued, fully paid and nonassessable and free
from all preemptive rights of any stockholder and free from all taxes, liens and charges in respect of the issue thereof. Certificates for Shares purchased hereunder shall be delivered to the Holder within a reasonable time after the date on which
this Warrant shall have been exercised as aforesaid. The Company further covenants and agrees that during the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved (or
will 

  
 2 

 
have provided for the ability to accomplish the same through a voting contract amongst sufficient stockholders), for the purpose of issue or transfer upon exercise of the subscription rights
evidenced by this Warrant, a sufficient number of shares of authorized but unissued Shares (together with the number of shares of Common Stock issuable upon conversion of such Shares), or other securities and property, when and as required for the
exercise of the rights represented by this Warrant. 
 3. Adjustment of Exercise Price and Number of Shares. The Exercise Price and
the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time upon the occurrence of certain events described in this Section 3. Whenever the number of Shares purchasable upon the exercise
of this Warrant is adjusted as herein provided the Exercise Price payable upon exercise of this Warrant shall be adjusted by multiplying the Exercise Price in effect immediately prior to such adjustment by a fraction, of which the numerator shall be
the number of Shares purchasable upon the exercise of this Warrant immediately prior to such adjustment, and of which the denominator shall be the number of Shares so purchasable immediately thereafter. 

(a) Conversion of Shares. If all of the outstanding Shares of the Company for which this Warrant is exercisable are converted into
shares of Common Stock, the number of Shares purchasable upon exercise of this Warrant immediately prior to such conversion shall be adjusted so that the Holder of this Warrant shall be entitled to receive the number of shares of Common Stock which
the Holder would have owned or have been entitled to receive had this Warrant been exercised immediately prior to such conversion and the Shares received thereupon had been simultaneously converted into shares of Common Stock immediately prior to
such event. 
 (b) Dilutive Issuances. The Holder of this Warrant shall be entitled to the benefit of all adjustments in the number
of shares of Common Stock of the Company issuable upon conversion of the Shares of the Company which occur after the date of this Warrant and prior to the exercise of this Warrant, including, without limitation, any increase in the number of shares
of Common Stock issuable upon conversion as a result of a dilutive issuance of capital stock. 
 (c) Split, Subdivision or Combination of
Shares. If the Company at any time while this Warrant, or any portion hereof, remains outstanding and unexpired shall split, subdivide or combine the Shares, into a different number of securities of the same class, the number of Shares
purchasable upon exercise of this Warrant immediately prior thereto shall be adjusted so that the holder of this Warrant shall be entitled to receive the kind and number of Shares or other securities of the Company which the Holder would have owned
or have been entitled to receive after the happening of any of the events described above, had this Warrant been exercised immediately prior to the happening of such event or any record date with respect thereto. An adjustment made pursuant to this
Section 3(c) shall become effective immediately after the effective date of such event retroactive to the record date, if any, for such event. 

(d) Reclassification. If the Company, at any time while this Warrant, or any portion hereof, remains outstanding and unexpired by
reclassification of securities or otherwise, shall change the Shares into the same or a different number of securities or any other class or 

  
 3 

 
classes, this Warrant shall thereafter represent the right to receive the kind and number of Shares or other securities of the Company which the Holder would have owned or have been entitled to
receive after the happening of the event described above, had this Warrant been exercised immediately prior to the happening of such event or any record date with respect thereto. An adjustment made pursuant to this Section 3(d) shall become
effective immediately after the effective date of such event retroactive to the record date, if any, for such event. 
 (e) Cash
Distributions. No adjustment on account of cash dividends or interest on the Shares will be made to the Exercise Price under this Warrant. 

(f) De Minimus Adjustments. No adjustment in the number of Shares purchasable hereunder shall be required unless such adjustment would
require an increase or decrease of at least one percent (1%) in the number of Shares purchasable upon the exercise of this Warrant; provided, however, that any adjustments which by reason of this Section 3(f) are not required to be made
shall be carried forward and taken into account in any subsequent adjustment. All calculations shall be made to the nearest cent and to the nearest one-hundredth of a Share, as the case may be. 

(g) Notice of Adjustment. Upon any adjustment of the Exercise Price or any increase or decrease in the number of shares purchasable
upon the exercise of this Warrant, the Company shall give written notice thereof, by first class mail postage prepaid, addressed to the registered Holder of this Warrant at the address of such Holder as shown on the books of the Company. The notice
shall be signed by the Company’s chief financial officer and shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of this
Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. 
 (h) Other
Notices. If at any time: 
 (i) The Company shall declare any cash dividend upon its Shares (or Common Stock issuable upon conversion
thereof); 
 (ii) There shall be any acquisition or capital reorganization or reclassification of the capital stock of the Company; 

(iii) There shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Company; or 

(iv) There shall be an initial public offering of the Company’s securities; 

then, in any one or more of said cases, the Company shall give, by first class mail, postage prepaid, addressed to the Holder of this Warrant at the address
of such Holder as shown on the books of the Company, (a) at least ten (10) days prior written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend or for determining rights to vote
in respect of any such acquisition, reorganization, reclassification, dissolution, liquidation, winding-up or public offering, and (b) in the case of any such acquisition, reorganization, reclassification, dissolution, liquidation, winding-up
or public offering, at least 

  
 4 

 
ten (10) days prior written notice of the date when the same shall take place; provided, however, that the Holder shall make a best efforts attempt to respond to such notice as early as
possible after the receipt thereof. Any notice given in accordance with the foregoing clause (a) shall also specify, in the case of any such dividend, the date on which the holders of Shares (or Common Stock issuable upon conversion thereof)
shall be entitled thereto. Any notice given in accordance with the foregoing clause (b) shall also specify the date on which the holders of Shares (or Common Stock issuable upon conversion thereof) shall be entitled to exchange their Shares (or
Common Stock issuable upon conversion thereof) for securities or other property deliverable upon such acquisition, reorganization, reclassification, dissolution, liquidation, winding-up, conversion or public offering, as the case may be. 

4. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of
this Warrant. With respect to any fraction of a share called for upon the exercise of this Warrant, an amount equal to such fraction multiplied by the then current price at which each Share may be purchased hereunder shall be paid in cash to the
Holder. 
 5. Charges, Taxes and Expenses. Issuance of certificates for Shares upon the exercise of this Warrant shall be made
without charge to the Holder hereof for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the
name of the Holder or such other name as specified on the Notice of Exercise delivered to the Company. 
 6. No Rights as
Stockholders. This Warrant does not entitle the Holder to any voting rights or other rights as a stockholder of the Company prior to the exercise thereof. 

7. Early Termination on Merger, Initial Public Offering, etc. If at any time the Company proposes to merge, reorganize or consolidate
with or into any other entity, sell all or substantially all of the assets of the Company, effect any other transaction or series of related transactions in which the holders of the Company’s capital stock immediately prior to the consummation
of such transaction(s) hold less than fifty percent (50%) of the voting power of the surviving entity (or its parent), or conduct an initial public offering of its capital stock, then the Company shall give the Holder notice of such transaction
pursuant to Section 3(h), and if the Warrant has not been exercised by the effective date of the transaction, the Warrant shall terminate. 

8. Loss, Theft, Destruction or Mutilation of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon reimbursement to the Company of all reasonable expenses incidental thereto, and upon
surrender and cancellation of this Warrant, if mutilated, the Company will make and deliver a new warrant of like tenor and dated as of such cancellation, in lieu of this Warrant. 

  
 5 

 9. Miscellaneous. 

(a) Issue Date. The provisions of this Warrant shall be construed and shall be given effect in all respects as if it had been issued
and delivered by the Company on the date set forth below. 
 (b) Governing Law. THIS WARRANT SHALL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES. 
 (c) Restrictions. By acceptance
hereof, the Holder acknowledges that the Shares acquired upon the exercise of this Warrant may have restrictions upon their resale imposed by state and federal securities laws, and that certain 2008 Stockholders’ Agreement, as amended. 

(d) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall be a Saturday or a Sunday or shall be a legal holiday, then such action may be taken or such right may be exercised on the next succeeding day not a Saturday, Sunday or legal holiday. 

(e) Waivers and Amendments. Any provision of this Warrant may be amended and the observance of any term of this Warrant may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Holder. 

(f) Assignment. This Warrant may be assigned or transferred by the Holder only with the prior written approval of the Company. 

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized. 

Dated: 
  

			
	EXAGEN DIAGNOSTICS, INC.
		
	By:	 	
		 	  

  
 6 

 NOTICE OF EXERCISE 

 

	TO:	Exagen Diagnostics, Inc. 

 801 University, S.E., Suite 209 

Albuquerque, New Mexico 87106 

ATTN: Secretary 
 1. The
undersigned hereby elects to purchase                  shares of Common Stock (the “Shares”) of Exagen Diagnostics, Inc. pursuant to the terms of the
attached Warrant, and tenders herewith payment of the purchase price in full. 
 2. Please issue a certificate or certificates representing
the Shares in the name of the undersigned or in such other name as is specified below: 
  

							
		 	  
	 	
		 	(Print Name)	 	
				
		 	Address:	 	  
	 	
			
		 	  
	 	

 3. The undersigned confirms that the Shares are being acquired for the account of the undersigned for
investment only and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or selling the Shares. 

 

					
	  
	 		 	  

	(Date)	 		 	(Signature)
			
		 		 	  

		 		 	(Print Name)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]